Makers Laboratories Ltd
Incorporated in 1984, Makers Laboratories
Ltd is in the business of manufacturing and marketing of pharmaceuticals
- Market Cap ₹ 74.3 Cr.
- Current Price ₹ 126
- High / Low ₹ 230 / 118
- Stock P/E
- Book Value ₹ 120
- Dividend Yield 0.00 %
- ROCE 4.25 %
- ROE 3.36 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.09 times its book value
Cons
- Company has a low return on equity of -4.47% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 69 | 127 | 101 | 104 | 121 | 131 | |
| 60 | 108 | 98 | 103 | 112 | 121 | |
| Operating Profit | 8 | 19 | 3 | 1 | 9 | 10 |
| OPM % | 12% | 15% | 3% | 1% | 7% | 7% |
| 1 | 3 | 2 | 2 | 11 | 2 | |
| Interest | 2 | 2 | 2 | 2 | 1 | 1 |
| Depreciation | 5 | 4 | 4 | 5 | 5 | 4 |
| Profit before tax | 3 | 16 | -1 | -4 | 13 | 6 |
| Tax % | 50% | 25% | 161% | 23% | 19% | |
| 1 | 12 | -2 | -5 | 11 | 4 | |
| EPS in Rs | -0.56 | 8.44 | -8.05 | -10.61 | 12.69 | -0.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -23% |
| TTM: | -100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 6% |
| 3 Years: | -2% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -4% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 6 | 6 | 6 | 6 |
| Reserves | 49 | 55 | 63 | 57 | 65 | 65 |
| 21 | 23 | 17 | 22 | 8 | 8 | |
| 62 | 62 | 66 | 76 | 70 | 78 | |
| Total Liabilities | 136 | 144 | 152 | 161 | 148 | 157 |
| 71 | 68 | 85 | 87 | 74 | 72 | |
| CWIP | 0 | 9 | 0 | 0 | 1 | 3 |
| Investments | 2 | 0 | 0 | 3 | 0 | 3 |
| 63 | 66 | 67 | 71 | 73 | 79 | |
| Total Assets | 136 | 144 | 152 | 161 | 148 | 157 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 18 | -9 | 1 | -4 | |
| 0 | -22 | 1 | -7 | 20 | |
| 0 | 0 | 6 | 6 | -16 | |
| Net Cash Flow | 0 | -3 | -2 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 88 | 39 | 72 | 70 | 84 |
| Inventory Days | 344 | 166 | 281 | 227 | 230 |
| Days Payable | 182 | 38 | 91 | 112 | 79 |
| Cash Conversion Cycle | 250 | 167 | 262 | 185 | 234 |
| Working Capital Days | 112 | 61 | 113 | 97 | 140 |
| ROCE % | 15% | 1% | -2% | 4% |
Documents
Announcements
-
Standalone And Consolidated Financial Results For Q2 And Half Year Ended 30.09.2025
3h - Unaudited Q2/H1 results ended Sep 30, 2025; consolidated H1 revenue Rs6,917.55 lakh, H1 PAT Rs203.31 lakh.
-
Board Meeting Outcome for Standalone And Consolidated Financial Results For Q2 And Half Year Ended 30.09.2025
3h - Unaudited Q2/H1 FY26 results: standalone H1 loss Rs58.39L; consolidated H1 profit Rs203.31L; board approved Nov 7, 2025.
-
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30.09.2025
16 Oct - Board meeting on 7 Nov 2025 to consider Q2/H1 unaudited results ended 30 Sep 2025; trading window closed.
-
Relodgement Of Transfer For Physical Shares - Sep 2025
10 Oct - Re-lodgement report of physical share transfer requests for month ended 30 September 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - Makers Laboratories: Reg 74(5) certificate confirming dematerialisation for quarter ended 30 Sep 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
The company markets 200+ generic formulations in India across major therapeutic segments like anti-malarial, antibiotics, anti-inflammatory, analgesics, and anti-diabetics, catering to dispensing doctors, nursing homes, and hospitals. It also undertakes job work for injectables (anti-malarial) for IPCA and procures products on a P2P basis from manufacturers in Himachal Pradesh and Uttarakhand's excise-free zones.